Skip to main content

Epidural Analgesia Has No Effect on Maternal Temperature


July 27, 2012 — Contrary to previous studies, there’s no significant relationship between epidural anesthesia and an increase in maternal body temperature during labor, according to a new study published in the August issue of Anesthesiology.
In contrast, the study, by Michael A. Frölich, MD, from the Department of Anesthesiology at the University of Alabama at Birmingham, and colleagues, did find significant associations between temperature increase during induced labor and both higher body mass index (P = .0067) and longer time from rupture of membranes to delivery (P = .0077).
Reports over recent years suggest that possible causes of noninfectious maternal temperature elevations during labor include epidural analgesia, endogenous heat production by uterine contractions, and overheated delivery rooms. The authors sought to evaluate the first possible cause by conducting a prospective cohort trial.
Of 90 women with induced labor who were enrolled in the study, 1 was excluded because of a clinical diagnosis of chorioamnionitis, and 4 were excluded because they received acetaminophen for intrapartum pain. An additional 4 participants were excluded because of the availability of less than 4 hours of data. A total of 81 women undergoing induced labor were therefore included in the analysis.
Labor lasted an average of 11 hours and 41 minutes. All but 3 of the women received epidural analgesia. The median duration of epidural analgesia was 7.9 hours (interquartile range, 4.3 - 12.1 hours).
The authors found that temperature increased with length of labor. They calculated a very small average temperature trend, with an increase of 0.017°C/hour (P = .0093) over the course of 10 hours of labor. The population slope was calculated using the linear mixed model, β1.
Fever in laboring women was not associated with epidural analgesia. The authors did note, however, the absence of a temperature drop in the first 4 hours after initiation of epidural anesthesia.
The authors found a significant association between the time of rupture of membranes to delivery and body mass index (P = .0475).
Previous studies have reported maternal temperature elevations in women who received epidural analgesia in association with placental inflammation, neonatal sepsis work-up, pregnancy-induced hypertension, labor progress, and mode of delivery.
Numerous theories have been proposed as to why the temperature increases occur during so many different labor circumstances. In a press release, Dr. Frölich stated, "Long labor sustains an inflammatory process that may result in a temperature elevation. Also, the same mechanism may be responsible for patients who are overweight, since the link between obesity and inflammation is well established."
The authors propose that future research focus on better understanding the exact causes of noninfectious maternal intrapartum fever to help identify and treat women who are more prone to fever during labor.
The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more